Rolinsatamab talirine

托洛林妥单抗

Report date: 2024/02/05 13:54:46

Base Information

Drug NameRolinsatamab talirine

Drug Alias NameDC-1630993h16fABBV-176

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VA linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > PBD dimer SGD-1882 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionDNA cross linking agentsProlactin receptor modulators

TargetsProlactin receptorDNA

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesDenmarkAustralia +[4]

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesAbbvie Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAbbvie Inc

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A